Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SIWA 318H
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SIWA Therapeutics To Participate in September Investor Conferences
Details : SIWA recently announced the results of a study demonstrating that 318H binds to both COVID-19 and Influenza A, thus showing promise for 318H to become a broad-spectrum antiviral drug.
Product Name : SIWA 318H
Product Type : Antibody
Upfront Cash : Inapplicable
September 16, 2020
Lead Product(s) : SIWA 318H
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable